|1.||Parsons, Andrew A: 1 article (02/2002)|
|2.||Barone, Frank C: 1 article (02/2002)|
|3.||Hart, Timothy K: 1 article (02/2002)|
|4.||Koster, Paul F: 1 article (02/2002)|
|5.||Ohlstein, Eliot H: 1 article (02/2002)|
|6.||Valocik, Richard E: 1 article (02/2002)|
|7.||Gabriel, Melanie A: 1 article (02/2002)|
|8.||Toomey, John R: 1 article (02/2002)|
|9.||McVey, Matt: 1 article (02/2002)|
|10.||Toomey, J R: 1 article (10/2000)|
10/01/2000 - "Pretreatment of rats with either SB 249417 (3.0 mg/kg, i. v.) or enoxaparin (30.0 mg/kg, i.v. or s.c.) resulted in comparable and significant reductions in thrombus formation. "
10/01/2000 - "A humanized inhibitory anti-factor IX(a) antibody (SB 249417) has been compared to enoxaparin (Lovenox) in a rat model of arterial thrombosis. "
10/01/2000 - "Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis."
02/01/2002 - "Treatment with SB 249417 (3.0 mg/kg) 2, 4, or 6 hours after stroke reduced infarct volumes by 44%, 50%, and 13% (P=NS), respectively. "
02/01/2002 - "In this study, using a rat thromboembolic stroke model, we investigated the use of an inhibitory anti-factor IX(a) monoclonal antibody (SB 249417) for the treatment of thromboembolic stroke and compared its efficacy to that of tPA. "
02/01/2002 - "This study suggests that cerebral ischemia and the resultant perfusion deficit are exacerbated by the activation of blood coagulation and that anticoagulants like SB 249417 may find utility in the treatment of ischemic stroke."
|3.||Brain Ischemia (Cerebral Ischemia)
|1.||Factor IX (PTC)
|3.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)